Humacyte, Inc. — Director's Dealing 2022

Dec 12, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-12-08

Reporting Person: Parikh Shamik J (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-08	Stock Options (right to buy)	$3.07	A	91120	Acquired	2032-12-08	Common Stock (91120.0)	Direct

Footnotes

F1: The first 25% of the option becomes exercisable on December 8, 2023, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2026.